1. Home
  2. BBIO vs VMI Comparison

BBIO vs VMI Comparison

Compare BBIO & VMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • VMI
  • Stock Information
  • Founded
  • BBIO 2015
  • VMI 1946
  • Country
  • BBIO United States
  • VMI United States
  • Employees
  • BBIO N/A
  • VMI N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • VMI Metal Fabrications
  • Sector
  • BBIO Health Care
  • VMI Industrials
  • Exchange
  • BBIO Nasdaq
  • VMI Nasdaq
  • Market Cap
  • BBIO 7.6B
  • VMI 6.5B
  • IPO Year
  • BBIO 2019
  • VMI N/A
  • Fundamental
  • Price
  • BBIO $41.73
  • VMI $318.41
  • Analyst Decision
  • BBIO Strong Buy
  • VMI Buy
  • Analyst Count
  • BBIO 13
  • VMI 3
  • Target Price
  • BBIO $56.67
  • VMI $362.50
  • AVG Volume (30 Days)
  • BBIO 2.5M
  • VMI 150.9K
  • Earning Date
  • BBIO 07-31-2025
  • VMI 07-23-2025
  • Dividend Yield
  • BBIO N/A
  • VMI 0.85%
  • EPS Growth
  • BBIO N/A
  • VMI 129.00
  • EPS
  • BBIO N/A
  • VMI 17.19
  • Revenue
  • BBIO $127,415,000.00
  • VMI $4,066,520,000.00
  • Revenue This Year
  • BBIO $102.05
  • VMI $1.10
  • Revenue Next Year
  • BBIO $54.69
  • VMI $4.93
  • P/E Ratio
  • BBIO N/A
  • VMI $18.66
  • Revenue Growth
  • BBIO N/A
  • VMI N/A
  • 52 Week Low
  • BBIO $21.62
  • VMI $250.07
  • 52 Week High
  • BBIO $41.90
  • VMI $379.22
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 69.82
  • VMI 50.11
  • Support Level
  • BBIO $39.65
  • VMI $318.02
  • Resistance Level
  • BBIO $41.36
  • VMI $330.03
  • Average True Range (ATR)
  • BBIO 1.51
  • VMI 5.71
  • MACD
  • BBIO 0.35
  • VMI -1.09
  • Stochastic Oscillator
  • BBIO 97.37
  • VMI 41.99

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About VMI Valmont Industries Inc.

Valmont Industries Inc, along with its subsidiaries, operates as a manufacturer of products and services for infrastructure and agriculture markets. Its reportable segments are Infrastructure and Agriculture. The company generates maximum revenue from the Infrastructure segment, which includes the manufacturing and distribution of products and solutions to serve the infrastructure markets of utility, solar, lighting and transportation, and telecommunications, along with coatings services to protect metal products. The Agriculture segment provides irrigation equipment components, including aftermarket parts and tubular products, and technology solutions for precision agriculture. Geographically, it derives key revenue from the United States, followed by Australia, Brazil, and other regions.

Share on Social Networks: